Lycera initiates phase2 trial of LYC-30937-EC for psoriasis

[Caroline]

This is an interesting, specifically different, approach.

Quote:

---

ATPase modulator, is designed to selectively target and induce cell death (apoptosis) in disease-causing immune cells (T-lymphocytes), while sparing normal cells. Chronically activated, pathogenic T-lymphocytes have unique metabolic features, allowing these cells to be targeted selectively by LYC-30937. Based on preclinical studies, LYC-30937 has therapeutic potential in inflammatory bowel diseases such as ulcerative colitis as well as in other autoimmune diseases.  Combined with the ability to localize drug delivery to the GI tract, LYC-30937-EC has the potential to avoid global immune suppression and other side effects associated with drugs currently administered systemically to treat inflammatory bowel disease, including UC and Crohn’s disease.

So it points to T-cells and is proven to work for ulcerative collitis.

ATPase itself is

An enzyme that catalyzes the formation of ATP from ADP, inorganic phosphate, and energy, found in mitochondria and chloroplasts; adenosine triphosphatase. Also called ATP synthase.

This as far as I can see related to the energy cycle of the cells, mitochondria.

Very interesting as it points also to other auto immune diseases. Like psoriasis and maybe also MS, might be a nice competitor for Tecfidera.    

P.s. Fred, two times a

Code:

[qt].  Blah blah  [/qt].

In one post doesn't seem to work.